GlassScriptPhysician profile
Charissa L Parker
NPI 1225503394
$8,665.13
in general payments reported to CMS, 2019-2025
58 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.48 · 2020: $137 · 2021: $1,749 · 2022: $2,526 · 2023: $2,173 · 2024: $1,601 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,221 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,221.09 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,417.55 | 2022 | |
| Amgen INC. | $579.37 | 2021-2025 | Krystexxa, Parsabiv, Tavneos |
| Abbvie INC. | $491.80 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $482.14 | 2022-2024 | Jynarque |
| Horizon Therapeutics Plc | $395.49 | 2023 | Krystexxa |
| Genzyme Corporation | $333.47 | 2021-2023 | |
| Veloxis Pharmaceuticals, INC. | $253.87 | 2022-2024 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $250.57 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $222.30 | 2020-2023 | Ultomiris |
| Novo Nordisk INC | $221.00 | 2022-2024 | Ozempic, Rybelsus, Rivfloza |
| Astrazeneca Pharmaceuticals LP | $217.20 | 2022-2024 | Lokelma, Farxiga |
| Merck Sharp & Dohme LLC | $211.04 | 2023-2024 | Prevymis, Dificid |
| Novartis Pharmaceuticals Corporation | $191.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.75 | 2022-2024 | Livtencity |
| Vifor Pharma, INC. | $166.84 | 2023-2024 | Veltassa |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charissa Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.